AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis LUND, Sweden, Feb. 05, 2024 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines...

AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis First-in-class, peripheral serotonin (5-HT2B) receptor antagonist being developed as a highly selective, oral, anti-fibrotic medicine for skin and lung disorders LUND, Sweden, May 23, 2023 (GLOBE...